| Filed On | Filing |
|---|---|
| 17 Sep 2026 |
Form 4: Maier Paul V, Director
Disposed of 30,000 Stock Options (Disposition to Issuer) |
| 15 Sep 2026 |
Form 4: Maier Paul V, Director
Sold 32,802 shares ($10.5K) |
| 11 Sep 2026 | 144 |
| 08 Sep 2026 |
8-K: Completion of Acquisition or Disposition of Assets
On September 1, 2026, International Stem Cell Corporation (the “Company”) completed the sale of 100% of the membership interests of its wholly-owned subsidiary, Lifeline Cell Technology, LLC (“LCT”), to American Type Culture Collection, ... |
| 13 Aug 2026 | 10-Q |
| 04 Aug 2026 | DEFINITIVE INFORMATION STATEMENT |
| 24 Jul 2026 | PRELIMINARY INFORMATION STATEMENT |
| 16 Jul 2026 | 8-K: Entry into a Material Definitive Agreement |
| 23 Jun 2026 |
Form 4: Don Wright, Director
Granted 212,584 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Maier Paul V, Director
Granted 212,584 Stock Option (Right to Buy) |
| 12 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 14 May 2026 | 10-Q |
| 29 Apr 2026 | ARS |
| 29 Apr 2026 |
Proxy statement: annual meeting on June 11, 2026
CEO pay $89K, up 33% |
| 30 Mar 2026 | 10-K |
| 18 Nov 2025 | 8-K: Submission of Matters to a Vote of Security Holders |
| 13 Nov 2025 | 10-Q |
| 16 Sep 2025 | 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation |
| 14 Aug 2025 | 10-Q |
| 20 Jun 2025 |
Form 4: Don Wright, Director
Granted 562,786 Stock Option (Right to Buy) |
Loading...
